By: IPP Bureau
Last updated : August 31, 2023 8:01 am
Prasugrel tablets are indicated to reduce the rate of thrombotic CV events
Unichem Laboratories Limited has received ANDA approval for its Prasugrel Tablets USP, 5 mg and 10 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Effient® (Prasugrel) Tablets, 5 mg and 10 mg, of Cosette Pharmaceuticals, Inc.
Prasugrel tablets are indicated to reduce the rate of thrombotic CV events (including stent thrombosis) in patients with acute coronary syndrome. The product will be commercialized from Unichem's Goa Plant.